董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Uri Geiger | 男 | Chairman of the Board | 55 | 7.75万美元 | 未持股 | 2023-09-25 |
| Samuel Rubinstein | 女 | Director | 84 | 8.00万美元 | 未持股 | 2023-09-25 |
| Robert Moccia | 男 | President, Chief Executive Officer and Director | 65 | 98.25万美元 | 未持股 | 2023-09-25 |
| Wayne Cafran | 男 | Director | 62 | 未披露 | 未持股 | 2023-09-25 |
| Irit Yaniv | 男 | Director | 59 | 未披露 | 未持股 | 2023-09-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Moccia | 男 | President, Chief Executive Officer and Director | 65 | 98.25万美元 | 未持股 | 2023-09-25 |
| Christopher Lesovitz | 男 | Chief Financial Officer | 41 | 40.78万美元 | 未持股 | 2023-09-25 |
| Shmuel Gov | 男 | Senior Vice President | 63 | 53.63万美元 | 未持股 | 2023-09-25 |
董事简历
中英对照 | 中文 | 英文- Uri Geiger
-
Uri Geiger，2014年1月以来，一直担任本公司董事。他现为Accelmed的管理合伙人，这是他在2009年参与创办的私募股权投资公司，专注于医疗器械公司的投资。此前，2006年5月至2008年12月，他是医疗技术公司Exalenz Bioscience Ltd的首席执行官。此前，他曾参与创办光学组件开发商GalayOr Networks，并在2001-2003年间担任首席执行官。他从2000年起，成为Dragon Variation Fund的创始合伙人，这是以色列首批对冲基金之一。1999年回到以色列之前，他在华尔街获得了资本市场方面的丰富知识和经验。他曾是Tel Aviv University’s Recanati School of Business的兼职教授，讲授私募股权和风投课程，出版了《Startup Companies and Venture Capital》、《From Concept to Wall Street》两本书。他在New York’s Columbia University Center for Law & Economics获得全球股票市场专业的博士学位。他还曾是以色列空军的少校。
Uri Geiger,is Strata Skin Sciences, Inc. Chairman of the Board. Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata's Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies. Dr. Geiger served as the Chairman of the Board of Directors of Cogentix Medical from November 2016 until its sale in April 2018 and he is currently on the board of a number of public and private medical device companies. Dr. Geiger has served on the board of directors of NeuroPace, Inc., a publicly traded medical device company focused on epilepsy, since January 2023 and Minerva Surgical, Inc., a publicly traded medical device company focused on uterine healthcare, since February 2023. - Uri Geiger，2014年1月以来，一直担任本公司董事。他现为Accelmed的管理合伙人，这是他在2009年参与创办的私募股权投资公司，专注于医疗器械公司的投资。此前，2006年5月至2008年12月，他是医疗技术公司Exalenz Bioscience Ltd的首席执行官。此前，他曾参与创办光学组件开发商GalayOr Networks，并在2001-2003年间担任首席执行官。他从2000年起，成为Dragon Variation Fund的创始合伙人，这是以色列首批对冲基金之一。1999年回到以色列之前，他在华尔街获得了资本市场方面的丰富知识和经验。他曾是Tel Aviv University’s Recanati School of Business的兼职教授，讲授私募股权和风投课程，出版了《Startup Companies and Venture Capital》、《From Concept to Wall Street》两本书。他在New York’s Columbia University Center for Law & Economics获得全球股票市场专业的博士学位。他还曾是以色列空军的少校。
- Uri Geiger,is Strata Skin Sciences, Inc. Chairman of the Board. Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata's Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies. Dr. Geiger served as the Chairman of the Board of Directors of Cogentix Medical from November 2016 until its sale in April 2018 and he is currently on the board of a number of public and private medical device companies. Dr. Geiger has served on the board of directors of NeuroPace, Inc., a publicly traded medical device company focused on epilepsy, since January 2023 and Minerva Surgical, Inc., a publicly traded medical device company focused on uterine healthcare, since February 2023.
- Samuel Rubinstein
-
Samuel Rubinstein自2018年5月29日起成为公司董事，并在审计委员会以及薪酬/提名和治理委员会任职。Rubinstein先生在Taro Pharmaceuticals Industries担任了20多年的首席执行官兼总经理，这是一家纳斯达克上市的皮肤病公司。在他的管理下，Taro成长为一家跨国公司，在全球拥有超过1000名员工，营业额接近4.5亿美元。2003年，鲁宾斯坦先生获得杰出工业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际营销课程。Rubinstein先生担任Clal Biotechnology Industries，Exalenz，Medison Biotech，Trima Pharma，Kamada的董事会成员，并担任Marcum和Sol-Gel Pharma的顾问。Milky还是特拉维夫Sourasky Medical Center附近Medical Research Fund和the National Authority for Yiddish Culture董事。
Samuel Rubinstein,has more than 25 years of experience in the venture capital, pharmaceutical and MedTech industries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and business skills. Dr. Yaniv has served as partner at Accelmed Ventures since 2012. During this time she led Eximo from pre-clinical development through acquisition. Dr. Irit Yaniv previously served as Executive Director and Chairperson of Accelmed's Innovation Hub portfolio companies, a global group of funds investing and acquiring control in HealthTech companies focused on Buyout and Non-Control transactions in commercial stage companies. Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School at Tel Aviv University. - Samuel Rubinstein自2018年5月29日起成为公司董事，并在审计委员会以及薪酬/提名和治理委员会任职。Rubinstein先生在Taro Pharmaceuticals Industries担任了20多年的首席执行官兼总经理，这是一家纳斯达克上市的皮肤病公司。在他的管理下，Taro成长为一家跨国公司，在全球拥有超过1000名员工，营业额接近4.5亿美元。2003年，鲁宾斯坦先生获得杰出工业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际营销课程。Rubinstein先生担任Clal Biotechnology Industries，Exalenz，Medison Biotech，Trima Pharma，Kamada的董事会成员，并担任Marcum和Sol-Gel Pharma的顾问。Milky还是特拉维夫Sourasky Medical Center附近Medical Research Fund和the National Authority for Yiddish Culture董事。
- Samuel Rubinstein,has more than 25 years of experience in the venture capital, pharmaceutical and MedTech industries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and business skills. Dr. Yaniv has served as partner at Accelmed Ventures since 2012. During this time she led Eximo from pre-clinical development through acquisition. Dr. Irit Yaniv previously served as Executive Director and Chairperson of Accelmed's Innovation Hub portfolio companies, a global group of funds investing and acquiring control in HealthTech companies focused on Buyout and Non-Control transactions in commercial stage companies. Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School at Tel Aviv University.
- Robert Moccia
-
Robert Moccia于2021年3月1日担任首席执行官和董事会成员。Moccia先生拥有超过20年的执行管理经验，担任小型到中型专业制药公司的总裁、首席运营官和首席执行官，以及超过35年的全球制药经验，在一般管理、运营、战略规划、业务发展、产品开发、销售、营销和建立以客户为中心的组织方面拥有专业知识。2014年，Moccia先生联合创立了Encore皮肤科。在创立Encore之前，Moccia先生是Precision Petrophics Inc.的首席执行官，该公司于2014年出售给Valeant。Moccia先生在美国销售和/或推出了30多种皮肤科产品。他在皮肤科领域完成了多项许可、收购和合作。Moccia先生曾在Medicis Pharmaceuticals Sr.担任执行管理职务。Graceway Pharmaceuticals（总裁兼首席运营官）和Bioglan Pharmaceuticals（总裁）的企业发展副总裁。他也曾在Dermik和Stiefel Laboratories工作，从事销售、营销和业务开发。Moccia先生拥有石山学院生物学学士学位。
Robert Moccia,assumed the duties of Chief Executive Officer and member of the Board on March 1, 2021. Mr. Moccia has more than 20 years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies and over 35 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations. In 2014 Mr. Moccia co-founded Encore Dermatology. Prior to founding Encore, Mr. Moccia was CEO of Precision Dermatology Inc., which was sold to Valeant in 2014. Mr. Moccia has marketed and/or launched over 30 dermatological products in the US. He has completed multiple licenses, acquisitions and partnerships in the dermatology space. Mr. Moccia has held executive management positions at Medicis Pharmaceuticals (Sr. VP of Corporate Development), Graceway Pharmaceuticals (President & COO), and Bioglan Pharmaceuticals (President). He also spent time at Dermik and Stiefel Laboratories in sales, marketing, and business development. Mr. Moccia holds a B.S. in Biology from Stonehill College. - Robert Moccia于2021年3月1日担任首席执行官和董事会成员。Moccia先生拥有超过20年的执行管理经验，担任小型到中型专业制药公司的总裁、首席运营官和首席执行官，以及超过35年的全球制药经验，在一般管理、运营、战略规划、业务发展、产品开发、销售、营销和建立以客户为中心的组织方面拥有专业知识。2014年，Moccia先生联合创立了Encore皮肤科。在创立Encore之前，Moccia先生是Precision Petrophics Inc.的首席执行官，该公司于2014年出售给Valeant。Moccia先生在美国销售和/或推出了30多种皮肤科产品。他在皮肤科领域完成了多项许可、收购和合作。Moccia先生曾在Medicis Pharmaceuticals Sr.担任执行管理职务。Graceway Pharmaceuticals（总裁兼首席运营官）和Bioglan Pharmaceuticals（总裁）的企业发展副总裁。他也曾在Dermik和Stiefel Laboratories工作，从事销售、营销和业务开发。Moccia先生拥有石山学院生物学学士学位。
- Robert Moccia,assumed the duties of Chief Executive Officer and member of the Board on March 1, 2021. Mr. Moccia has more than 20 years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies and over 35 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations. In 2014 Mr. Moccia co-founded Encore Dermatology. Prior to founding Encore, Mr. Moccia was CEO of Precision Dermatology Inc., which was sold to Valeant in 2014. Mr. Moccia has marketed and/or launched over 30 dermatological products in the US. He has completed multiple licenses, acquisitions and partnerships in the dermatology space. Mr. Moccia has held executive management positions at Medicis Pharmaceuticals (Sr. VP of Corporate Development), Graceway Pharmaceuticals (President & COO), and Bioglan Pharmaceuticals (President). He also spent time at Dermik and Stiefel Laboratories in sales, marketing, and business development. Mr. Moccia holds a B.S. in Biology from Stonehill College.
- Wayne Cafran
-
韦恩·卡夫兰是MyNextSeason的一名顾问，卡夫兰先生将自己的创业精神和30多年的“四大”领导力运用到他的客户工作中。他擅长应对行业演变和制定转型战略；作为毕马威前负责人，他领导医疗咨询服务，负责关键客户的监督、增长和业务发展。卡夫兰还曾担任医疗保健内部审计业务的全国负责人，在客户服务的各个方面提供协助和咨询，并担任公司最大客户的主要合伙人。此前，他启动了公司的医疗保健内部审计业务，推动了市场份额的大幅增长。作为审计委员会的重要顾问，他在治理实践、内部控制和监管改革方面拥有丰富的经验。卡夫兰先生在整个职业生涯中都表现出对指导他人的热爱，他是教练专业卓越协会的认证专业教练。他热衷于在各个层面促进多样性，曾担任毕马威非裔美国人商业资源集团和毕马威退伍军人商业资源集团的冠军。他目前担任安靠健康的董事，曾担任解放项目的董事会主席和审计委员会主席。他拥有宾厄姆顿大学政治学学士学位和纽约大学卫生金融公共管理硕士学位。
Wayne Cafran,is an Advisor for MyNextSeason, Mr. Cafran applies his entrepreneurial spirit and more than 30 years of Big Four leadership to his client work. He is practiced at responding to industry evolutions and creating transformational strategies; as a former Principal with KPMG, led Healthcare Advisory services with responsibility for oversight, growth, and business development of key accounts. Mr. Cafran also served as a national leader for the Healthcare Internal Audit practice, assisting and advising on all aspects of client services, as well as acting as lead partner to the firm's largest clients. Previously, he started the firm's Healthcare Internal Audit practice, where he drove significant market share growth. A valued advisor to audit committees, he has deep experience with governance practice, internal controls, and regulatory change. Mr. Cafran has demonstrated a career-long devotion to mentoring others and is a Certified Professional Coach from the Institute for Professional Excellence in Coaching. Passionate about promoting diversity at all levels, he served as a Champion on KPMG's African American Business Resources Group as well as KPMG's Veterans Business Resource Group.He currently serves as a Board Director for EmblemHealth and was previously a Board Chair and Audit Committee Chair for Liberation Programs. He holds a BA in Political Science from Binghamton University and a Master of Public Administration in Health Finance from New York University. - 韦恩·卡夫兰是MyNextSeason的一名顾问，卡夫兰先生将自己的创业精神和30多年的“四大”领导力运用到他的客户工作中。他擅长应对行业演变和制定转型战略；作为毕马威前负责人，他领导医疗咨询服务，负责关键客户的监督、增长和业务发展。卡夫兰还曾担任医疗保健内部审计业务的全国负责人，在客户服务的各个方面提供协助和咨询，并担任公司最大客户的主要合伙人。此前，他启动了公司的医疗保健内部审计业务，推动了市场份额的大幅增长。作为审计委员会的重要顾问，他在治理实践、内部控制和监管改革方面拥有丰富的经验。卡夫兰先生在整个职业生涯中都表现出对指导他人的热爱，他是教练专业卓越协会的认证专业教练。他热衷于在各个层面促进多样性，曾担任毕马威非裔美国人商业资源集团和毕马威退伍军人商业资源集团的冠军。他目前担任安靠健康的董事，曾担任解放项目的董事会主席和审计委员会主席。他拥有宾厄姆顿大学政治学学士学位和纽约大学卫生金融公共管理硕士学位。
- Wayne Cafran,is an Advisor for MyNextSeason, Mr. Cafran applies his entrepreneurial spirit and more than 30 years of Big Four leadership to his client work. He is practiced at responding to industry evolutions and creating transformational strategies; as a former Principal with KPMG, led Healthcare Advisory services with responsibility for oversight, growth, and business development of key accounts. Mr. Cafran also served as a national leader for the Healthcare Internal Audit practice, assisting and advising on all aspects of client services, as well as acting as lead partner to the firm's largest clients. Previously, he started the firm's Healthcare Internal Audit practice, where he drove significant market share growth. A valued advisor to audit committees, he has deep experience with governance practice, internal controls, and regulatory change. Mr. Cafran has demonstrated a career-long devotion to mentoring others and is a Certified Professional Coach from the Institute for Professional Excellence in Coaching. Passionate about promoting diversity at all levels, he served as a Champion on KPMG's African American Business Resources Group as well as KPMG's Veterans Business Resource Group.He currently serves as a Board Director for EmblemHealth and was previously a Board Chair and Audit Committee Chair for Liberation Programs. He holds a BA in Political Science from Binghamton University and a Master of Public Administration in Health Finance from New York University.
- Irit Yaniv
-
Irit Yaniv，成为公司董事，自2018年5月29日起生效。Rubinstein先生在制药和医疗设备领域拥有多年经验，包括担任Taro Pharmaceuticals Industries首席执行官和总经理20多年，监督该公司被SUN Pharma成功收购。2003年，鲁宾斯坦先生获得了杰出实业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际市场营销课程。鲁宾斯坦先生是MediWound Ltd.、MedisonBiotech、Trima Pharma（他担任董事长）和KSDG的董事会成员。他曾在Exalenz（被VIVO收购）、Kamada（KMDA）和Clal Biotechnology Industries（CBI）的董事会任职，是Sol-Gel Pharma的顾问。鲁宾斯坦还是特拉维夫苏拉斯基医学中心和国家意第绪文化管理局附近的医学研究基金的主任。
Irit Yaniv,became a director of the Company effective May 29, 2018. Mr. Rubinstein years of experience in the pharmaceutical and medical device fields include having served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Industries, overseeing its successful acquisition by SUN Pharma.. In 2003, Mr. Rubinstein received the Exceptional Industrialist award. During these years he also finished an International Marketing Course at the Wharton School of the University of Pennsylvania. Mr. Rubinstein serves as a board member on the boards of Mediwound Ltd., Medison Biotech, Trima Pharma (where he serves as chairman), and KSDG. He previously served on the boards of Exalenz (acquired by VIVO), Kamada (KMDA), and Clal Biotechnology Industries (CBI), and is a consultant to Sol-Gel Pharma. Mr. Rubinstein is also a director at the Medical Research Fund near The Tel Aviv Sourasky Medical Center and The National Authority for Yiddish Culture. - Irit Yaniv，成为公司董事，自2018年5月29日起生效。Rubinstein先生在制药和医疗设备领域拥有多年经验，包括担任Taro Pharmaceuticals Industries首席执行官和总经理20多年，监督该公司被SUN Pharma成功收购。2003年，鲁宾斯坦先生获得了杰出实业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际市场营销课程。鲁宾斯坦先生是MediWound Ltd.、MedisonBiotech、Trima Pharma（他担任董事长）和KSDG的董事会成员。他曾在Exalenz（被VIVO收购）、Kamada（KMDA）和Clal Biotechnology Industries（CBI）的董事会任职，是Sol-Gel Pharma的顾问。鲁宾斯坦还是特拉维夫苏拉斯基医学中心和国家意第绪文化管理局附近的医学研究基金的主任。
- Irit Yaniv,became a director of the Company effective May 29, 2018. Mr. Rubinstein years of experience in the pharmaceutical and medical device fields include having served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Industries, overseeing its successful acquisition by SUN Pharma.. In 2003, Mr. Rubinstein received the Exceptional Industrialist award. During these years he also finished an International Marketing Course at the Wharton School of the University of Pennsylvania. Mr. Rubinstein serves as a board member on the boards of Mediwound Ltd., Medison Biotech, Trima Pharma (where he serves as chairman), and KSDG. He previously served on the boards of Exalenz (acquired by VIVO), Kamada (KMDA), and Clal Biotechnology Industries (CBI), and is a consultant to Sol-Gel Pharma. Mr. Rubinstein is also a director at the Medical Research Fund near The Tel Aviv Sourasky Medical Center and The National Authority for Yiddish Culture.
高管简历
中英对照 | 中文 | 英文- Robert Moccia
Robert Moccia于2021年3月1日担任首席执行官和董事会成员。Moccia先生拥有超过20年的执行管理经验，担任小型到中型专业制药公司的总裁、首席运营官和首席执行官，以及超过35年的全球制药经验，在一般管理、运营、战略规划、业务发展、产品开发、销售、营销和建立以客户为中心的组织方面拥有专业知识。2014年，Moccia先生联合创立了Encore皮肤科。在创立Encore之前，Moccia先生是Precision Petrophics Inc.的首席执行官，该公司于2014年出售给Valeant。Moccia先生在美国销售和/或推出了30多种皮肤科产品。他在皮肤科领域完成了多项许可、收购和合作。Moccia先生曾在Medicis Pharmaceuticals Sr.担任执行管理职务。Graceway Pharmaceuticals（总裁兼首席运营官）和Bioglan Pharmaceuticals（总裁）的企业发展副总裁。他也曾在Dermik和Stiefel Laboratories工作，从事销售、营销和业务开发。Moccia先生拥有石山学院生物学学士学位。
Robert Moccia,assumed the duties of Chief Executive Officer and member of the Board on March 1, 2021. Mr. Moccia has more than 20 years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies and over 35 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations. In 2014 Mr. Moccia co-founded Encore Dermatology. Prior to founding Encore, Mr. Moccia was CEO of Precision Dermatology Inc., which was sold to Valeant in 2014. Mr. Moccia has marketed and/or launched over 30 dermatological products in the US. He has completed multiple licenses, acquisitions and partnerships in the dermatology space. Mr. Moccia has held executive management positions at Medicis Pharmaceuticals (Sr. VP of Corporate Development), Graceway Pharmaceuticals (President & COO), and Bioglan Pharmaceuticals (President). He also spent time at Dermik and Stiefel Laboratories in sales, marketing, and business development. Mr. Moccia holds a B.S. in Biology from Stonehill College.- Robert Moccia于2021年3月1日担任首席执行官和董事会成员。Moccia先生拥有超过20年的执行管理经验，担任小型到中型专业制药公司的总裁、首席运营官和首席执行官，以及超过35年的全球制药经验，在一般管理、运营、战略规划、业务发展、产品开发、销售、营销和建立以客户为中心的组织方面拥有专业知识。2014年，Moccia先生联合创立了Encore皮肤科。在创立Encore之前，Moccia先生是Precision Petrophics Inc.的首席执行官，该公司于2014年出售给Valeant。Moccia先生在美国销售和/或推出了30多种皮肤科产品。他在皮肤科领域完成了多项许可、收购和合作。Moccia先生曾在Medicis Pharmaceuticals Sr.担任执行管理职务。Graceway Pharmaceuticals（总裁兼首席运营官）和Bioglan Pharmaceuticals（总裁）的企业发展副总裁。他也曾在Dermik和Stiefel Laboratories工作，从事销售、营销和业务开发。Moccia先生拥有石山学院生物学学士学位。
- Robert Moccia,assumed the duties of Chief Executive Officer and member of the Board on March 1, 2021. Mr. Moccia has more than 20 years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies and over 35 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations. In 2014 Mr. Moccia co-founded Encore Dermatology. Prior to founding Encore, Mr. Moccia was CEO of Precision Dermatology Inc., which was sold to Valeant in 2014. Mr. Moccia has marketed and/or launched over 30 dermatological products in the US. He has completed multiple licenses, acquisitions and partnerships in the dermatology space. Mr. Moccia has held executive management positions at Medicis Pharmaceuticals (Sr. VP of Corporate Development), Graceway Pharmaceuticals (President & COO), and Bioglan Pharmaceuticals (President). He also spent time at Dermik and Stiefel Laboratories in sales, marketing, and business development. Mr. Moccia holds a B.S. in Biology from Stonehill College.
- Christopher Lesovitz
Christopher Lesovitz，自2021年7月11日起，Lesovitz先生担任公司财务总监。此前，他在一家完全整合的皮肤科公司Encore Dermatology，Inc.领导财务部。在此之前，Lesovitz先生在专门从事疼痛管理的制药公司Iroko Pharmaceuticals，LLC担任过各种财务职务，担任助理财务总监和高级会计经理。莱索维茨先生于2004年获得维拉诺瓦大学会计学学士学位。此外，Lesovitz先生是宾夕法尼亚州的注册会计师（CPA）。
Christopher Lesovitz,Since July 11, 2021, Mr. Lesovitz has served as the Company's Controller. Previously, he led the finance department at Encore Dermatology, Inc., a fully integrated dermatology company. Prior to that, Mr. Lesovitz held various finance roles with Iroko Pharmaceuticals, LLC, a pharmaceutical company specializing in pain management, serving as its Assistant Controller and as its Senior Accounting Manager. Mr. Lesovitz received his Bachelor of Science in accounting from Villanova University in 2004. Additionally, Mr. Lesovitz is a Certified Public Accountant (CPA) in the Commonwealth of Pennsylvania.- Christopher Lesovitz，自2021年7月11日起，Lesovitz先生担任公司财务总监。此前，他在一家完全整合的皮肤科公司Encore Dermatology，Inc.领导财务部。在此之前，Lesovitz先生在专门从事疼痛管理的制药公司Iroko Pharmaceuticals，LLC担任过各种财务职务，担任助理财务总监和高级会计经理。莱索维茨先生于2004年获得维拉诺瓦大学会计学学士学位。此外，Lesovitz先生是宾夕法尼亚州的注册会计师（CPA）。
- Christopher Lesovitz,Since July 11, 2021, Mr. Lesovitz has served as the Company's Controller. Previously, he led the finance department at Encore Dermatology, Inc., a fully integrated dermatology company. Prior to that, Mr. Lesovitz held various finance roles with Iroko Pharmaceuticals, LLC, a pharmaceutical company specializing in pain management, serving as its Assistant Controller and as its Senior Accounting Manager. Mr. Lesovitz received his Bachelor of Science in accounting from Villanova University in 2004. Additionally, Mr. Lesovitz is a Certified Public Accountant (CPA) in the Commonwealth of Pennsylvania.
- Shmuel Gov
Shmuel Gov是公司高级副总裁兼总经理，负责公司在加利福尼亚州卡尔斯巴德的制造和研发工厂的运营。他于2015年加入公司，担任副总裁兼总经理。他在医疗器械制造、物流和研发领域拥有超过25年的经验。他拥有电子工程和国际商业管理学位。
Shmuel Gov,is the Company's Senior Vice President and General Manager in charge of operations at the Company's manufacturing and R&D facility in Carlsbad, CA. He joined the Company in 2015 as Vice President and General Manager. He has over 25 years of experience in medical device manufacturing, logistics, and R&D. He holds degrees in electronics engineering and international business management.- Shmuel Gov是公司高级副总裁兼总经理，负责公司在加利福尼亚州卡尔斯巴德的制造和研发工厂的运营。他于2015年加入公司，担任副总裁兼总经理。他在医疗器械制造、物流和研发领域拥有超过25年的经验。他拥有电子工程和国际商业管理学位。
- Shmuel Gov,is the Company's Senior Vice President and General Manager in charge of operations at the Company's manufacturing and R&D facility in Carlsbad, CA. He joined the Company in 2015 as Vice President and General Manager. He has over 25 years of experience in medical device manufacturing, logistics, and R&D. He holds degrees in electronics engineering and international business management.